Publicação

BioRePortAP, an electronic clinical record coupled with a database : an example of its use in a single

Ver documento

Detalhes bibliográficos
Resumo:Aims: To evaluate the efficacy and safety of the treatment of psoriatic arthritis (PsA) patients with tumor necrosis factor (TNF) antagonists in the Rheumatology Department of Hospital de Santa Maria using the BioRePortAP. Methods: The Portuguese Society of Rheumatology (SPR) developed an electronic medical chart coupled with a database for the follow up of PsA patients, the BioRePortAP, which was launched in May 2009. This evaluation was based on all the PsA patients that were on active treatment with TNF antagonists in September 2009 and were registered in the BioRePortAP. All the previous data on these patients were introduced in BioRePortAP using the prospective paper based follow up protocol that this Department was using since 1999. Only patients with more than 9 months of treatment were analyzed. Results: Forty-two patients with PsA, actively treated with anti-TNF agents in September 2009, for at least 9 months, were analyzed in BioRePortAP. Twenty-three patients were male (55%) and nineteen were female (45%). The average age of these patients was 49.8±10.9 years old, the average disease duration was of 10.7±5.6 years and the mean duration of biological therapy was of 37.8±27.8 months. For the 81% of patients with peripheral joint disease there was a mean reduction of more than 80% in the swollen and tender joint counts, and almost 50% in the health assessment questionnaire (HAQ) value. In the 19% of the patients with axial involvement the reduction of BASDAI and BASFI was not statistically significative. On top of that, PASI score suffered a reduction of 64%. Fourteen patients (33.3%) had to switch their TNF antagonist treatment. 58.8% of the switches were due to adverse effects and 41.2% due to therapy failure. Regarding the 56 adverse reactions registered, only one was a severe reaction. The remaining adverse reactions were not severe and 67% of them were due to infections. Discussion: The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA. The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs.
Autores principais:Campanilho-Marques, R.
Outros Autores:Polido-Pereira, J.; Rodrigues, A.; Ramos, F.; Saavedra, M. J.; Costa, M.; Martins, F.; Pereira da Silva, José A.; Canhao, Helena; Fonseca, João Eurico
Assunto:Psoriatic arthritis Registry BioReportAP Biological therapy Portugal
Ano:2010
País:Portugal
Tipo de documento:artigo
Tipo de acesso:acesso aberto
Instituição associada:Universidade de Lisboa
Idioma:inglês
Origem:Repositório da Universidade de Lisboa
_version_ 1866809995523260416
author Campanilho-Marques, R.
author2 Polido-Pereira, J.
Rodrigues, A.
Ramos, F.
Saavedra, M. J.
Costa, M.
Martins, F.
Pereira da Silva, José A.
Canhao, Helena
Fonseca, João Eurico
author2_role author
author
author
author
author
author
author
author
author
author_facet Campanilho-Marques, R.
Polido-Pereira, J.
Rodrigues, A.
Ramos, F.
Saavedra, M. J.
Costa, M.
Martins, F.
Pereira da Silva, José A.
Canhao, Helena
Fonseca, João Eurico
author_role author
contributor_name_str_mv Repositório Científico de Acesso Aberto da ULisboa
country_str PT
creators_json_txt [{\"Person.name\":\"Campanilho-Marques, R.\"},{\"Person.name\":\"Polido-Pereira, J.\"},{\"Person.name\":\"Rodrigues, A.\"},{\"Person.name\":\"Ramos, F.\"},{\"Person.name\":\"Saavedra, M. J.\"},{\"Person.name\":\"Costa, M.\"},{\"Person.name\":\"Martins, F.\"},{\"Person.name\":\"Pereira da Silva, José A.\"},{\"Person.name\":\"Canhao, Helena\",\"Person.identifier.orcid\":\"0000-0002-3239-2809\"},{\"Person.name\":\"Fonseca, João Eurico\",\"Person.identifier.orcid\":\"0000-0003-1432-3671\"}]
datacite.contributors.contributor.contributorName.fl_str_mv Repositório Científico de Acesso Aberto da ULisboa
datacite.creators.creator.creatorName.fl_str_mv Campanilho-Marques, R.
Polido-Pereira, J.
Rodrigues, A.
Ramos, F.
Saavedra, M. J.
Costa, M.
Martins, F.
Pereira da Silva, José A.
Canhao, Helena
Fonseca, João Eurico
datacite.date.Accepted.fl_str_mv 2010-01-01T00:00:00Z
datacite.date.available.fl_str_mv 2012-05-03T15:03:57Z
datacite.date.embargoed.fl_str_mv 2012-05-03T15:03:57Z
datacite.rights.fl_str_mv http://purl.org/coar/access_right/c_abf2
datacite.subjects.subject.fl_str_mv Psoriatic arthritis
Registry
BioReportAP
Biological therapy
Portugal
datacite.titles.title.fl_str_mv BioRePortAP, an electronic clinical record coupled with a database : an example of its use in a single
dc.contributor.none.fl_str_mv Repositório Científico de Acesso Aberto da ULisboa
dc.creator.none.fl_str_mv Campanilho-Marques, R.
Polido-Pereira, J.
Rodrigues, A.
Ramos, F.
Saavedra, M. J.
Costa, M.
Martins, F.
Pereira da Silva, José A.
Canhao, Helena
Fonseca, João Eurico
dc.date.Accepted.fl_str_mv 2010-01-01T00:00:00Z
dc.date.available.fl_str_mv 2012-05-03T15:03:57Z
dc.date.embargoed.fl_str_mv 2012-05-03T15:03:57Z
dc.format.none.fl_str_mv application/pdf
dc.identifier.none.fl_str_mv http://hdl.handle.net/10451/6203
dc.language.none.fl_str_mv eng
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Reumatologia
dc.rights.none.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.subject.none.fl_str_mv Psoriatic arthritis
Registry
BioReportAP
Biological therapy
Portugal
dc.title.fl_str_mv BioRePortAP, an electronic clinical record coupled with a database : an example of its use in a single
dc.type.none.fl_str_mv http://purl.org/coar/resource_type/c_6501
description Aims: To evaluate the efficacy and safety of the treatment of psoriatic arthritis (PsA) patients with tumor necrosis factor (TNF) antagonists in the Rheumatology Department of Hospital de Santa Maria using the BioRePortAP. Methods: The Portuguese Society of Rheumatology (SPR) developed an electronic medical chart coupled with a database for the follow up of PsA patients, the BioRePortAP, which was launched in May 2009. This evaluation was based on all the PsA patients that were on active treatment with TNF antagonists in September 2009 and were registered in the BioRePortAP. All the previous data on these patients were introduced in BioRePortAP using the prospective paper based follow up protocol that this Department was using since 1999. Only patients with more than 9 months of treatment were analyzed. Results: Forty-two patients with PsA, actively treated with anti-TNF agents in September 2009, for at least 9 months, were analyzed in BioRePortAP. Twenty-three patients were male (55%) and nineteen were female (45%). The average age of these patients was 49.8±10.9 years old, the average disease duration was of 10.7±5.6 years and the mean duration of biological therapy was of 37.8±27.8 months. For the 81% of patients with peripheral joint disease there was a mean reduction of more than 80% in the swollen and tender joint counts, and almost 50% in the health assessment questionnaire (HAQ) value. In the 19% of the patients with axial involvement the reduction of BASDAI and BASFI was not statistically significative. On top of that, PASI score suffered a reduction of 64%. Fourteen patients (33.3%) had to switch their TNF antagonist treatment. 58.8% of the switches were due to adverse effects and 41.2% due to therapy failure. Regarding the 56 adverse reactions registered, only one was a severe reaction. The remaining adverse reactions were not severe and 67% of them were due to infections. Discussion: The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA. The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs.
dirty 0
eu_rights_str_mv openAccess
format article
fulltext.url.fl_str_mv https://repositorio.ulisboa.pt/bitstreams/718c5736-d7c9-483c-9845-8685b42d88a1/download
id ul_d9caa1cb1ac97cb4e3815153cd3d53d3
identifier.url.fl_str_mv http://hdl.handle.net/10451/6203
instacron_str ul
institution Universidade de Lisboa
instname_str Universidade de Lisboa
language eng
network_acronym_str ul
network_name_str Repositório da Universidade de Lisboa
oai_identifier_str oai:repositorio.ulisboa.pt:10451/6203
organization_str_mv urn:organizationAcronym:ul
person_str_mv Campanilho-Marques, R.
Polido-Pereira, J.
Rodrigues, A.
Ramos, F.
Saavedra, M. J.
Costa, M.
Martins, F.
Pereira da Silva, José A.
Canhao, Helena
Canhao, Helena
http://orcid.org/0000-0002-3239-2809
0000-0002-3239-2809
Fonseca, João Eurico
Fonseca, João Eurico
https://www.ciencia-id.pt/F310-B85D-57C7
F310-B85D-57C7
http://orcid.org/0000-0003-1432-3671
0000-0003-1432-3671
publishDate 2010
publisher.none.fl_str_mv Sociedade Portuguesa de Reumatologia
reponame_str Repositório da Universidade de Lisboa
repository_id_str urn:repositoryAcronym:ul
service_str_mv urn:repositoryAcronym:ul
spelling engSociedade Portuguesa de ReumatologiaengAims: To evaluate the efficacy and safety of the treatment of psoriatic arthritis (PsA) patients with tumor necrosis factor (TNF) antagonists in the Rheumatology Department of Hospital de Santa Maria using the BioRePortAP. Methods: The Portuguese Society of Rheumatology (SPR) developed an electronic medical chart coupled with a database for the follow up of PsA patients, the BioRePortAP, which was launched in May 2009. This evaluation was based on all the PsA patients that were on active treatment with TNF antagonists in September 2009 and were registered in the BioRePortAP. All the previous data on these patients were introduced in BioRePortAP using the prospective paper based follow up protocol that this Department was using since 1999. Only patients with more than 9 months of treatment were analyzed. Results: Forty-two patients with PsA, actively treated with anti-TNF agents in September 2009, for at least 9 months, were analyzed in BioRePortAP. Twenty-three patients were male (55%) and nineteen were female (45%). The average age of these patients was 49.8±10.9 years old, the average disease duration was of 10.7±5.6 years and the mean duration of biological therapy was of 37.8±27.8 months. For the 81% of patients with peripheral joint disease there was a mean reduction of more than 80% in the swollen and tender joint counts, and almost 50% in the health assessment questionnaire (HAQ) value. In the 19% of the patients with axial involvement the reduction of BASDAI and BASFI was not statistically significative. On top of that, PASI score suffered a reduction of 64%. Fourteen patients (33.3%) had to switch their TNF antagonist treatment. 58.8% of the switches were due to adverse effects and 41.2% due to therapy failure. Regarding the 56 adverse reactions registered, only one was a severe reaction. The remaining adverse reactions were not severe and 67% of them were due to infections. Discussion: The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA. The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs.application/pdfengBioRePortAP, an electronic clinical record coupled with a database : an example of its use in a singleCampanilho-Marques, R.Polido-Pereira, J.Rodrigues, A.Ramos, F.Saavedra, M. J.Costa, M.Martins, F.Pereira da Silva, José A.PersonalCanhao, HelenaDSpacehttp://dspace.org/items/48f3be39-37f9-44de-9c7e-22e49a89efe5DSpacehttp://dspace.org/items/48f3be39-37f9-44de-9c7e-22e49a89efe5CanhaoHelenaORCIDhttp://orcid.org0000-0002-3239-2809Scopus Author IDhttps://www.scopus.com6602393492PersonalFonseca, João EuricoDSpacehttp://dspace.org/items/1772dc12-7c55-4c76-ae2d-c23270172480DSpacehttp://dspace.org/items/1772dc12-7c55-4c76-ae2d-c23270172480FonsecaJoãoCiência IDhttps://www.ciencia-id.ptF310-B85D-57C7ORCIDhttp://orcid.org0000-0003-1432-3671Scopus Author IDhttps://www.scopus.com7101983519Scopus Author IDhttps://www.scopus.com55881559500HostingInstitutionOrganizationalRepositório Científico de Acesso Aberto da ULisboae-mailmailto:repositorio@reitoria.ulisboa.ptrepositorio@reitoria.ulisboa.ptURLhttp://arp.spreumatologia.pt/download.php?filename=ARP_2010_2_176_11__AO_-_BioReportAR_ARP2010_58AO.pdfISSNIsPartOf0303-464X2012-05-03T15:03:57Z20102010-01-01T00:00:00ZHandlehttp://hdl.handle.net/10451/6203http://purl.org/coar/access_right/c_abf2open accessPsoriatic arthritisRegistryBioReportAPBiological therapyPortugal105711 bytesliteraturehttp://purl.org/coar/resource_type/c_6501journal articlehttp://purl.org/coar/access_right/c_abf2application/pdffulltexthttps://repositorio.ulisboa.pt/bitstreams/718c5736-d7c9-483c-9845-8685b42d88a1/downloadActa Reumatologica Portuguesa176183
spellingShingle BioRePortAP, an electronic clinical record coupled with a database : an example of its use in a single
Campanilho-Marques, R.
Psoriatic arthritis
Registry
BioReportAP
Biological therapy
Portugal
status SINGLETON
subject.fl_str_mv Psoriatic arthritis
Registry
BioReportAP
Biological therapy
Portugal
title BioRePortAP, an electronic clinical record coupled with a database : an example of its use in a single
title_full BioRePortAP, an electronic clinical record coupled with a database : an example of its use in a single
title_fullStr BioRePortAP, an electronic clinical record coupled with a database : an example of its use in a single
title_full_unstemmed BioRePortAP, an electronic clinical record coupled with a database : an example of its use in a single
title_short BioRePortAP, an electronic clinical record coupled with a database : an example of its use in a single
title_sort BioRePortAP, an electronic clinical record coupled with a database : an example of its use in a single
topic Psoriatic arthritis
Registry
BioReportAP
Biological therapy
Portugal
topic_facet Psoriatic arthritis
Registry
BioReportAP
Biological therapy
Portugal
url http://hdl.handle.net/10451/6203
visible 1